Lets^®

Therapeutic Segment:
Aromatase inhibitor

Generic Name:
Letrozole

Description:
Lets tablets for oral administration contains 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.

Indication:
• First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
• Adjuvant treatment of oestrogen receptor positive invasive early breast cancer in postmenopausal women.
• Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other antiestrogen therapy has failed.
• Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.
• Neo adjuvant treatment in postmenopausal women with localized hormone receptor positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated.

Formulation:

• Tablets

Strength:

• 2.5mg

Pack Size:

• 10’s